Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $260.7 million.

  • Fulcrum Therapeutics' Liabilities and Shareholders Equity fell 22.99% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $947.1 million, marking a year-over-year decrease of 10.95%. This contributed to the annual value of $260.7 million for FY2024, which is 1.17% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $260.7 million for FY2024, which was up 1.17% from $257.7 million recorded in FY2023.
  • Fulcrum Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $260.7 million during FY2024, with a 5-year trough of $129.6 million in FY2020.
  • Over the past 3 years, Fulcrum Therapeutics' median Liabilities and Shareholders Equity value was $257.7 million (recorded in 2023), while the average stood at $248.4 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Liabilities and Shareholders Equity surged by 81.36% in 2021, and later dropped by 3.54% in 2022.
  • Fulcrum Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $129.6 million in 2020, then spiked by 81.36% to $235.0 million in 2021, then decreased by 3.54% to $226.7 million in 2022, then grew by 13.68% to $257.7 million in 2023, then increased by 1.17% to $260.7 million in 2024.